Virax Biolabs Group Limited (VRAX) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Virax Biolabs Group Limited (VRAX) closed at USD 1.62 on 2026-10-15, a change of -89.1 % over the past year, with a market capitalization of USD 1.95M.
Virax Biolabs Group Limited recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-15 | 1.62 |
| 2026-10-14 | 1.65 |
| 2026-10-13 | 1.74 |
| 2026-10-12 | 1.85 |
| 2026-10-09 | 1.87 |
| 2026-10-08 | 1.99 |
| 2026-10-07 | 2.11 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Virax Biolabs Group Limited key figures
- Previous close
- USD 1.62 (2026-10-15)
- 1-year change
- -89.1 %
- Market cap
- USD 1.95M
- Enterprise value
- USD -5.51M
- P/E ratio (trailing)
- -0.12
- P/E ratio (forward)
- -0.24
- EPS (trailing)
- -12.64
- EPS (forward)
- -6.00
- PEG ratio
- n/a
- Price to book
- 0.11
- Revenue growth
- 684.9 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.19
- Employees
- 26
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Virax Biolabs Group Limited and compare it with other stocks.
Analyze VRAXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Virax Biolabs Group Limited shares.